Asthma & Status Asthmaticus

Asthma is chronic inflammation of the airways with bronchial hyperresponsiveness — the airway overreacts to triggers that barely bother a healthy lung. When symptoms flare, expiratory airflow falls for three reasons: the airways become narrower (bronchoconstriction), the airway walls thicken, and there is more mucus. Symptoms — wheezing, cough, shortness of breath, chest tightness — come and go, last hours to days, are classically worse at night and in the early morning, and resolve when the trigger is removed or medication is given.

What separates asthma from fixed airway disease is that the obstruction is characteristically reversible: patients show bronchodilator responsiveness on spirometry, and the air trapping and hyperinflation seen on chest imaging during an exacerbation can resolve. An exacerbation (attack, flare-up) is an acute or sub-acute worsening of symptoms and lung function compared with the patient’s usual state — and severe exacerbations can be fatal even in people with infrequent symptoms, which is why every asthma patient needs an action plan, not just the ones who seem sick.

In allergic asthma, IgE antibodies sit bound to high-affinity receptors on mast cells and basophils. On re-exposure to the trigger, mast cells degranulate, releasing histamine, prostaglandin D2, and the cysteinyl leukotrienes (LTC4/LTD4/LTE4) — mediators that contract airway smooth muscle and tighten the airway within minutes. This is the early phase, and it is the pharmacology map of the disorder: beta-2 agonists relax the muscle the mediators contracted, and leukotriene modifiers block the leukotriene arm directly.

Within the next several hours the late phase arrives: eosinophils, basophils, neutrophils, and helper and memory T cells localize to the airway. Th2 lymphocytes drive this inflammation — they produce IL-4, IL-5, IL-13, and GM-CSF; IL-3 and IL-5 sustain the eosinophils and basophils, and IL-13 drives remodeling, fibrosis, and hyperplasia. This late, cellular phase is why an attack that seemed to respond can rebound hours later, and it is the phase corticosteroids exist to treat.

Repeat this cycle for years without control and the airway remodels: the basement membrane thickens, myofibroblasts deposit collagen, and epithelial cells shed with loss of their tight junctions. Remodeling is the reason chronic uncontrolled asthma progresses — and part of why controller therapy matters even when the patient feels fine.

During an attack, airflow obstruction comes from a triad: airway smooth-muscle contraction (bronchospasm) + airway-wall edema + mucus plugging — with airway remodeling added chronically. Narrowed airways empty slowly, so in a severe exacerbation the airways close prematurely during exhalation before the lungs finish emptying. Gas stacks up behind them — air trapping — and functional residual capacity climbs. Trapped, poorly ventilated regions still receive blood flow, so ventilation–perfusion mismatch produces hypoxemia and lactic acidosis.

The blood gas tells the story in two acts, and reading it wrong is the classic exam trap. Act one: the hypoxemic patient breathes fast, blowing off CO₂ — the early ABG shows respiratory alkalosis with a low PaCO₂. Act two: the patient tires. The respiratory muscles can no longer sustain that minute ventilation, and PaCO₂ drifts up — through “normal” and beyond. In a patient still in obvious distress, a “normal” PaCO₂ of 40 mmHg indicates severe airflow obstruction and a heightened risk of respiratory failure; hypercarbia plus hypoxemia means respiratory failure is impending. A normalizing PaCO₂ in a tiring asthmatic is deterioration wearing improvement’s clothes.

Status asthmaticus is a severe, life-threatening exacerbation marked by persistent bronchospasm unresponsive to standard bronchodilators and corticosteroids — a medical emergency characterized by hypoxemia, hypercarbia, and secondary respiratory failure. Common precipitants are viral respiratory infections, allergen exposure, medication noncompliance, and environmental pollutants. The highest-risk patient is the one with a history of near-fatal asthma requiring intubation — the single greatest predictor of death from asthma — along with poor perception of dyspnea, recurrent hospitalizations despite chronic oral steroids, delayed presentation, and altered mental status.

The bedside signature of deterioration is a ladder of sound: a loud expiratory wheeze means air is still moving; diminishing breath sounds mean less air is moving; a silent chest means almost no alveolar airflow — a pre-arrest emergency. Wheezing is unreliable in severe exacerbations precisely because it may be absent when alveolar airflow is significantly impaired: the quieter chest signals worsening obstruction, not improvement. GINA is explicit — transfer to intensive care if the patient is drowsy, confused, or has a silent chest.

Rescue-inhaler behavior predicts who ends up here. Regular or over-use of SABA itself worsens the disease — it increases allergic responses and airway inflammation and reduces the bronchodilator response to SABA. Dispensing three or more 200-dose SABA canisters a year is associated with increased severe-exacerbation risk, and twelve or more with increased risk of asthma death. The patient reaching for the blue inhaler daily is not managing their asthma; they are documenting its loss of control.